Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.



from The Medical News http://ift.tt/16rb2q1